Companies: 10,795·Total market cap: $144.5T
Repligen Corporation

Repligen Corporation

RGENNASDAQHealthcare● Active
$122.31
$-4.24(-3.35%)
Market Cap$6.9B
P/E Ratio
52W High$175.77
52W Low$100.99

Repligen Corporation (RGEN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

rgen · stock forecast · 24 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 24 Wall Street analysts in the past 3 months

SellBuy

Buy

24 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
20
Hold
3
Sell
0
Strong Sell
0
Total: 24 · Buy rate: 87.5%

12-Month Price Target

High

$200

Consensus

$163

+33.4% upside

Low

$142

Median: $160 · Last Close: $122.31

The Repligen Corporation (RGEN) analyst consensus is Buy, based on ratings from 24 Wall Street analysts over the past 3 months. The average 12-month RGEN price target is $163.14, representing +33.4% upside from the current price of $122.31.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $163 (33.4%)

Consensus Target

$163.14

33.4% upside

High Target

$200

63.5%

Low Target

$142

16.1%

Current Price

$122.31

as of today

Based on analyst price targets, the RGEN stock price prediction for the next 12 months ranges from $142 to $200. The consensus RGEN price forecast of $163.14 implies 33.4% upside from the current price of $122.31.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$127.504.25%

1-day model range: $126.75–$128.26. Peak: $128.26 (+4.25%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$101-17.8%
2028$90-26.6%
2029$84-31.3%
2030$81-33.9%
2031-35.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%0%50%
7Buy
0Neutral
7Sell
RSI (14)75.8Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · RGEN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$122.96SELL
MA 10$120.49BUY
MA 20$115.45BUY
MA 50$118.72BUY
MA 100$128.27SELL
MA 200$137.76SELL
Current $RGEN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$122.65SELL
EMA 10$120.59BUY
EMA 20$118.72BUY
EMA 50$120.31BUY
EMA 100$126.36SELL
EMA 200$132.46SELL
Current $RGEN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HSBC2026-06-03
Maintains
BuyBuy
JP Morgan2026-05-06
Maintains
OverweightOverweight
Barclays2026-05-06
Maintains
OverweightOverweight
Canaccord Genuity2026-04-20
Maintains
HoldHold
Barclays2026-04-14
Maintains
OverweightOverweight
Evercore ISI Group2026-04-06
Maintains
OutperformOutperform
HC Wainwright & Co.2026-03-23
Maintains
BuyBuy
Wells Fargo2026-02-25
Maintains
OverweightOverweight
Barclays2026-02-25
Maintains
OverweightOverweight
UBS2026-02-25
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Repligen Corporation (RGEN) stock. Of the recent 107 rating actions, 6 were upgrades and 2 were downgrades. 24 analysts currently cover RGEN.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

RGEN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$823M

↓ 24.2% YoY

Revenue Next Year

$945M

↑ 14.9% YoY

EPS This Year

$2.00

EPS Next Year

$2.58

↑ 29.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RGEN EPS of $2.00 for the current fiscal year, based on estimates from 12 analysts. The RGEN revenue forecast is $823M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The RGEN stock forecast is supported by two independent data sources: analyst consensus ratings from 24 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RGEN price target is $163.14 (+33.4% upside), with an analyst consensus of Buy.

The RGEN short-term stock prediction for tomorrow is $127.50 (+4.25%). The RGEN stock price prediction for 2027 estimates an average of $101. The RGEN stock prediction for 2030 projects a range of $76–$86.

Repligen Corporation trades on NASDAQ under the ticker RGEN. The RGEN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

RGEN forecast · 8 questions

According to 24 Wall Street analysts, the average 12-month RGEN price target is $163.14, with a high forecast of $200.00 and a low of $142.00. The median price target is shown in the chart above when available. This implies +33.4% potential upside from the current price of $122.31.

RGEN price targetWhat is RGEN price targetRGEN analyst price targetRGEN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.